Merck reports Q4 adjusted EPS $1.72, consensus $1.67
Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including ...
Merck projects $64.1B-$65.6B revenue in 2025 amid WINREVAIR growth and GARDASIL rebasing
Q4 2024 Management View Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted ...
MarketWatch21d
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors
Shares of Merck & Co. Inc. MRK shed 1.32% to $99.65 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 ...
MarketWatch25d
Merck & Co. Inc. stock underperforms Friday when compared to competitors
Shares of Merck & Co. Inc. MRK sank 0.60% to $99.25 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.54% to 5,827.04 and ...